fibrosis therapy (Sankyo/FibroGen)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug Namefibrosis therapy (Sankyo/FibroGen)
Drug Alias NameTGF-B inhibitors (FibroGen/Sankyo)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTransforming growth factor beta receptors antagonists
TargetsTransforming growth factor beta receptors
Therapy Area/IndicationsFibrosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesJapan
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesFibrogen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesFibrogen IncSankyo Co Ltd
Active IndicationsN/A
Inactive IndicationsFibrosis

Other Information

ATC CodeN/A
Related LinksN/A